Corgenix Highlights AspirinWorks® Test at Pri-Med South 2011

February 9, 2011


For Immediate Release
Corgenix Highlights AspirinWorks® Test at Pri-Med South 2011

Simple, non-invasive test measures aspirin effect

DENVER — February 9, 2011 — Anti-platelet therapy and testing for aspirin effect are sure to be discussed at the February 10–13 Pri-Med® South 2011 conference in Fort Lauderdale, Fla. During the conference, Corgenix Medical Corp. (OTC BB: CONX) will highlight its AspirinWorks® Test for aspirin effect in booth No. 902 at the Broward County Convention Center.

AspirinWorks is a simple, non-invasive lab test performed on a urine specimen. It is the only FDA-cleared test that helps doctors accurately determine aspirin effect in apparently healthy individuals by measuring the urine levels of 11-dehydro thromboxane B2 (11-dhTxB2), a metabolite of thromboxane, the target of aspirin therapy. Individuals with high levels of 11- dhTxB2 are at increased risk of cardiovascular events, including stroke, myocardial infarction and cardiac death.

“Not everyone responds the same to the same dose of aspirin, and this test recognizes that fact,” said Gordon Ens, Clinical Affairs Director for Corgenix Medical Corp. “Aspirin effect is real, it can be measured, and it can be effectively treated by increasing dosage or changing therapy.”

Corgenix representatives will be on-hand during the conference to answer questions about the AspirinWorks Test, which will be offered to qualified attendees during regular exhibit hours February 11-13 in booth No. 902. Test results will be provided after the conference.

The AspirinWorks Test was launched in the U.S. in June 2007 following FDA 510(k) clearance, and it is now available nationwide through major medical laboratories, including Quest Diagnostics, LabCorp, SpectraCell, Health Diagnostic Laboratory and others.

Unlike functional platelet tests, which require freshly drawn blood that must be evaluated within at least four hours, the AspirinWorks Test is performed on a random urine sample that can be obtained in any doctor’s office or patient service center, making the test convenient for both physician and patient. Physicians and laboratories interested in ordering the test can call 1-800- 729-5661 x180, or email More information is also available at

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at

Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’ s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’ s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

Company Contact:
Corgenix Medical Corp.
William Critchfield, Senior VP and CFO Phone: 303-453-8903

Media Contact:
Armada Medical Marketing
Dan Snyders, Vice President and Public Relations Supervisor Phone: 303-623-1190 x230